Finance

Lists
Why is LENZ down 4.49%?
Dive Deeper
LENZ:NASDAQ
Lenz Therapeutics Inc
$3.62
-4.49%
(-0.17) 1D
$3.68
+1.66% (+0.060)
After hours
Closed: Oct 7, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LENZ...
Open
$3.72
High
$3.72
Low
$3.58
Mkt. cap
113.74M
Avg. vol.
738.24K
Volume
0.00
52-wk high
$49.24
52-wk low
$3.46
EPS
-$4.08
Beta
0.65
Shares outstanding
31.42M
No. of employees
152
Open
$3.72
High
$3.72
Low
$3.58
Mkt. cap
113.74M
Avg. vol.
738.24K
Volume
0.00
52-wk high
$49.24
52-wk low
$3.46
EPS
-$4.08
Beta
0.65
Shares outstanding
31.42M
No. of employees
152
News stories
From web sources and news partners
About Lenz Therapeutics Inc
CEO-
Employees152
Founded2013
HeadquartersSolana Beach, California, United States
SectorPharmaceutical industry
Websitelenz-tx.com
Analyst ratings
Based on 6 analysts giving stock ratings to LENZ in the past 3 months
Buy
Buy
4
Hold
2
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for LENZ in the last 3 months.
Highest
Current $3.62
$60.00 (+1,557.46%)
Average
$24.40 (+574.03%)
Lowest
$7.00 (+93.37%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason Gerberry
Bank of America Securities
Hold
Downgraded
$7.00
+93.4%
08/12/2026
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
08/12/2026
Biren Amin
Piper Sandler
Hold
Maintained
$7.00
+93.4%
08/12/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$10.00
+176.2%
08/13/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
$38.00
+949.7%
08/12/2026
Stacy Ku
TD Cowen
Buy
Reiterated
$60.00
+1,557.5%
08/12/2026
Last report
Aug 11, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$1.02 / -$1.07
+5.10%beat
Revenue / Est. (USD)
5.49M / 2.38M
+130.76%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
12.50M
1.59M
1.90M
5.49M
Cost of goods sold
-
418.00K
1.08M
280.00K
Cost of revenue
-
418.00K
1.08M
280.00K
Research and development expenses
3.79M
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27.60M
39.63M
44.96M
39.38M
Operating expense
31.39M
39.63M
44.96M
39.38M
Total operating expenses
31.39M
40.05M
46.04M
39.66M
Operating income
-18.89M
-38.46M
-44.14M
-34.17M
Other non operating income
-14.00K
-417.00K
3.00K
-13.00K
EBT including unusual items
-16.70M
-35.89M
-41.49M
-31.92M
EBT excluding unusual items
-16.70M
-35.89M
-41.49M
-31.92M
Income tax expense
-
2.00K
-
3.00K
Effective tax rate
-
-0.01%
-
-0.01%
Other operating expenses
-
-
-
-
Net income
-16.70M
-35.90M
-41.49M
-31.92M
Net profit margin
-133.60%
-2,260.45%
-2,182.43%
-581.81%
Earnings per share
-0.59
-1.16
-1.32
-1.02
Interest and investment income
2.20M
2.99M
2.64M
2.27M
Interest expense
-
-
-
-
Net interest expenses
2.20M
2.99M
2.64M
2.27M
Depreciation and amortization charges
-
-
-
-
EBITDA
-18.76M
-38.36M
-44.02M
-34.06M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps